Karyopharm Therapeutics's total assets for Q1 2025 were $127.71M, a decrease of -22.33% from the previous quarter. KPTI total liabilities were $333.60M for the fiscal quarter, a -4.81% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.